APO Research
Talk to an analyst

APO RESEARCH · REPORT

23-Valent Pneumococcal Polysaccharide Vaccine

23-Valent Pneumococcal Polysaccharide Vaccine is a vaccine product category defined by its pneumococcal antigen composition and formulation.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

23-Valent Pneumococcal Polysaccharide Vaccine is a kind of vaccine used to prevent infection caused by pneumococcal bacteria. 23-Valent Pneumococcal Polysaccharide Vaccine contains 23 of the most common types of pneumococcal bacteria.

23-Valent Pneumococcal Polysaccharide Vaccine is for use only in adults and children who are at least 2 years old. For children younger than 2 years old, another vaccine called Prevnar (pneumococcal conjugate vaccine [PCV] 7-valent) is used, usually given between the ages of 2 months and 15 months.

Antigen composition, conjugation status, presentation and labelled indications distinguish supplied vaccines. Products with different compositions are not interchangeable solely because a headline count is similar.

The commercial boundary

The selected edition describes a market scope. Product approvals, labelled use and clinical acceptance require their own evidence; neither report segmentation nor an illustrative image establishes medical suitability.

Which antigen composition and formulation define the vaccine?

Antigen composition, conjugation status, presentation and labelled indications distinguish supplied vaccines. Products with different compositions are not interchangeable solely because a headline count is similar.

Selected research

Market Analysis & Forecast

Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Analysis and Forecast 2026-2032

2 January 2026195 pages

Choose your research edition.

Industry Research23-Valent Pneumococcal Polysaccharide Vaccine Industry Research Report 2026113 pages · $2,950 USDIndustry Growth & TrendsGlobal 23-Valent Pneumococcal Polysaccharide Vaccine Industry Growth and Trends Forecast to 203272 pages · $3,450 USDMarket StructureGlobal 23-Valent Pneumococcal Polysaccharide Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032172 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal 23-Valent Pneumococcal Polysaccharide Vaccine Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal 23-Valent Pneumococcal Polysaccharide Vaccine Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

23-Valent Pneumococcal Polysaccharide Vaccine is a kind of vaccine used to prevent infection caused by pneumococcal bacteria. 23-Valent Pneumococcal Polysaccharide Vaccine contains 23 of the most common types of pneumococcal bacteria.

23-Valent Pneumococcal Polysaccharide Vaccine is for use only in adults and children who are at least 2 years old. For children younger than 2 years old, another vaccine called Prevnar (pneumococcal conjugate vaccine [PCV] 7-valent) is used, usually given between the ages of 2 months and 15 months.

The major players in global 23-Valent Pneumococcal Polysaccharide Vaccine market include MSD, Sanofipasteur, etc. The top 2 players occupy about 80% shares of the global market. North America and Europe are main markets, they occupy about 50% of the global market. Single Dose Vial is the main type, with a share about 60%. For Children (2-10) is the main application, which holds a share about 40%.

Read the full market overview

This report presents an overview of global market for 23-Valent Pneumococcal Polysaccharide Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of 23-Valent Pneumococcal Polysaccharide Vaccine, also provides the sales of main regions and countries. Of the upcoming market potential for 23-Valent Pneumococcal Polysaccharide Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the 23-Valent Pneumococcal Polysaccharide Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global 23-Valent Pneumococcal Polysaccharide Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for 23-Valent Pneumococcal Polysaccharide Vaccine sales, projected growth trends, production technology, application and end-user industry.

23-Valent Pneumococcal Polysaccharide Vaccine Segment by Company

MSD

Sanofipasteur

CDIBP

23-Valent Pneumococcal Polysaccharide Vaccine Segment by Type

Single Dose Vial

Pre-filled Syringe

23-Valent Pneumococcal Polysaccharide Vaccine Segment by Application

For Children (2-10)

For Person (10-64)

For The Old (Above or equal to 65)

23-Valent Pneumococcal Polysaccharide Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global 23-Valent Pneumococcal Polysaccharide Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of 23-Valent Pneumococcal Polysaccharide Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of 23-Valent Pneumococcal Polysaccharide Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of 23-Valent Pneumococcal Polysaccharide Vaccine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of 23-Valent Pneumococcal Polysaccharide Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, 23-Valent Pneumococcal Polysaccharide Vaccine sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Single Dose Vial Major Manufacturers Table 3. Pre-filled Syringe Major Manufacturers Table 4. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. For Children (2-10) Major Manufacturers Table 6. For Person (10-64) Major Manufacturers Table 7. For The Old (Above or equal to 65) Major Manufacturers Table 8. 23-Valent Pneumococcal Polysaccharide Vaccine Industry Trends Table 9. 23-Valent Pneumococcal Polysaccharide Vaccine Industry Drivers Table 10. 23-Valent Pneumococcal Polysaccharide Vaccine Industry Opportunities and Challenges Table 11. 23-Valent Pneumococcal Polysaccharide Vaccine Industry Restraints Table 12. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 13. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 14. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 15. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Region (2021-2026) Table 16. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Region (2027-2032) Table 17. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Dose) Table 18. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Region (2021-2026) & (K Dose) Table 19. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Region (2027-2032) & (K Dose) Table 20. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Region (2021-2026) Table 21. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Region (2027-2032) Table 22. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 23. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Manufacturers (2021-2026) Table 24. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Manufacturers (US$ Million) & (2021-2026) Table 25. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Manufacturers (2021-2026) Table 26. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Price (US$/Dose) of Manufacturers (2021-2026) Table 27. Global 23-Valent Pneumococcal Polysaccharide Vaccine Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 28. Global 23-Valent Pneumococcal Polysaccharide Vaccine Key Manufacturers Manufacturing Sites & Headquarters Table 29. Global 23-Valent Pneumococcal Polysaccharide Vaccine Manufacturers, Product Type & Application Table 30. Global 23-Valent Pneumococcal Polysaccharide Vaccine Manufacturers' Establishment Date Table 31. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 32. Global 23-Valent Pneumococcal Polysaccharide Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 33. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 35. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 36. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Type (2021-2026) Table 37. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Type (2027-2032) Table 38. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Type 2021 VS 2025 VS 2032 (K Dose) Table 39. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Type (2021-2026) & (K Dose) Table 40. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Type (2027-2032) & (K Dose) Table 41. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Type (2021-2026) Table 42. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Type (2027-2032) Table 43. Global 23-Valent Pneumococcal Polysaccharide Vaccine Price by Type (2021-2026) & (US$/Dose) Table 44. Global 23-Valent Pneumococcal Polysaccharide Vaccine Price by Type (2027-2032) & (US$/Dose) Table 45. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 46. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 47. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 48. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Application (2021-2026) Table 49. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Application (2027-2032) Table 50. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Application 2021 VS 2025 VS 2032 (K Dose) Table 51. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Application (2021-2026) & (K Dose) Table 52. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Application (2027-2032) & (K Dose) Table 53. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Application (2021-2026) Table 54. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Application (2027-2032) Table 55. Global 23-Valent Pneumococcal Polysaccharide Vaccine Price by Application (2021-2026) & (US$/Dose) Table 56. Global 23-Valent Pneumococcal Polysaccharide Vaccine Price by Application (2027-2032) & (US$/Dose) Table 57. MSD Company Information Table 58. MSD Business Overview Table 59. MSD 23-Valent Pneumococcal Polysaccharide Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 60. MSD 23-Valent Pneumococcal Polysaccharide Vaccine Product Portfolio Table 61. MSD Recent Development Table 62. Sanofipasteur Company Information Table 63. Sanofipasteur Business Overview Table 64. Sanofipasteur 23-Valent Pneumococcal Polysaccharide Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 65. Sanofipasteur 23-Valent Pneumococcal Polysaccharide Vaccine Product Portfolio Table 66. Sanofipasteur Recent Development Table 67. CDIBP Company Information Table 68. CDIBP Business Overview Table 69. CDIBP 23-Valent Pneumococcal Polysaccharide Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 70. CDIBP 23-Valent Pneumococcal Polysaccharide Vaccine Product Portfolio Table 71. CDIBP Recent Development Table 72. North America 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 73. North America 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 74. North America 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Type (2021-2026) & (K Dose) Table 75. North America 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Type (2027-2032) & (K Dose) Table 76. North America 23-Valent Pneumococcal Polysaccharide Vaccine Sales Price by Type (2021-2026) & (US$/Dose) Table 77. North America 23-Valent Pneumococcal Polysaccharide Vaccine Sales Price by Type (2027-2032) & (US$/Dose) Table 78. North America 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 79. North America 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 80. North America 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Application (2021-2026) & (K Dose) Table 81. North America 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Application (2027-2032) & (K Dose) Table 82. North America 23-Valent Pneumococcal Polysaccharide Vaccine Sales Price by Application (2021-2026) & (US$/Dose) Table 83. North America 23-Valent Pneumococcal Polysaccharide Vaccine Sales Price by Application (2027-2032) & (US$/Dose) Table 84. North America 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 85. North America 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 86. North America 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 87. North America 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2021 VS 2025 VS 2032) & (K Dose) Table 88. North America 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2021-2026) & (K Dose) Table 89. North America 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2027-2032) & (K Dose) Table 90. North America 23-Valent Pneumococcal Polysaccharide Vaccine Sales Price by Country (2021-2026) & (US$/Dose) Table 91. North America 23-Valent Pneumococcal Polysaccharide Vaccine Sales Price by Country (2027-2032) & (US$/Dose) Table 92. United States 23-Valent Pneumococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 93. Canada 23-Valent Pneumococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 94. Mexico 23-Valent Pneumococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 95. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 96. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 97. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Type (2021-2026) & (K Dose) Table 98. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Type (2027-2032) & (K Dose) Table 99. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Sales Price by Type (2021-2026) & (US$/Dose) Table 100. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Sales Price by Type (2027-2032) & (US$/Dose) Table 101. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 102. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 103. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Application (2021-2026) & (K Dose) Table 104. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Application (2027-2032) & (K Dose) Table 105. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Sales Price by Application (2021-2026) & (US$/Dose) Table 106. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Sales Price by Application (2027-2032) & (US$/Dose) Table 107. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 108. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 109. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 110. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2021 VS 2025 VS 2032) & (K Dose) Table 111. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2021-2026) & (K Dose) Table 112. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2027-2032) & (K Dose) Table 113. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Sales Price by Country (2021-2026) & (US$/Dose) Table 114. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Sales Price by Country (2027-2032) & (US$/Dose) Table 115. Germany 23-Valent Pneumococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 116. France 23-Valent Pneumococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 117. U.K. 23-Valent Pneumococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 118. Italy 23-Valent Pneumococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 119. Russia 23-Valent Pneumococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 120. Spain 23-Valent Pneumococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 121. Netherlands 23-Valent Pneumococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 122. Switzerland 23-Valent Pneumococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 123. Sweden 23-Valent Pneumococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 124. Poland 23-Valent Pneumococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 125. China 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 126. China 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 127. China 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Type (2021-2026) & (K Dose) Table 128. China 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Type (2027-2032) & (K Dose) Table 129. China 23-Valent Pneumococcal Polysaccharide Vaccine Sales Price by Type (2021-2026) & (US$/Dose) Table 130. China 23-Valent Pneumococcal Polysaccharide Vaccine Sales Price by Type (2027-2032) & (US$/Dose) Table 131. China 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 132. China 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 133. China 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Application (2021-2026) & (K Dose) Table 134. China 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Application (2027-2032) & (K Dose) Table 135. China 23-Valent Pneumococcal Polysaccharide Vaccine Sales Price by Application (2021-2026) & (US$/Dose) Table 136. China 23-Valent Pneumococcal Polysaccharide Vaccine Sales Price by Application (2027-2032) & (US$/Dose) Table 137. Asia 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 138. Asia 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 139. Asia 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Type (2021-2026) & (K Dose) Table 140. Asia 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Type (2027-2032) & (K Dose) Table 141. Asia 23-Valent Pneumococcal Polysaccharide Vaccine Sales Price by Type (2021-2026) & (US$/Dose) Table 142. Asia 23-Valent Pneumococcal Polysaccharide Vaccine Sales Price by Type (2027-2032) & (US$/Dose) Table 143. Asia 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 144. Asia 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 145. Asia 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Application (2021-2026) & (K Dose) Table 146. Asia 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Application (2027-2032) & (K Dose) Table 147. Asia 23-Valent Pneumococcal Polysaccharide Vaccine Sales Price by Application (2021-2026) & (US$/Dose) Table 148. Asia 23-Valent Pneumococcal Polysaccharide Vaccine Sales Price by Application (2027-2032) & (US$/Dose) Table 149. Asia 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 150. Asia 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 151. Asia 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 152. Asia 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2021 VS 2025 VS 2032) & (K Dose) Table 153. Asia 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2021-2026) & (K Dose) Table 154. Asia 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2027-2032) & (K Dose) Table 155. Asia 23-Valent Pneumococcal Polysaccharide Vaccine Sales Price by Country (2021-2026) & (US$/Dose) Table 156. Asia 23-Valent Pneumococcal Polysaccharide Vaccine Sales Price by Country (2027-2032) & (US$/Dose) Table 157. Japan 23-Valent Pneumococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 158. South Korea 23-Valent Pneumococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 159. India 23-Valent Pneumococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 160. Australia 23-Valent Pneumococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 161. Taiwan 23-Valent Pneumococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 162. Southeast Asia 23-Valent Pneumococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 163. SAMEA 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 164. SAMEA 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 165. SAMEA 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Type (2021-2026) & (K Dose) Table 166. SAMEA 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Type (2027-2032) & (K Dose) Table 167. SAMEA 23-Valent Pneumococcal Polysaccharide Vaccine Sales Price by Type (2021-2026) & (US$/Dose) Table 168. SAMEA 23-Valent Pneumococcal Polysaccharide Vaccine Sales Price by Type (2027-2032) & (US$/Dose) Table 169. SAMEA 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 170. SAMEA 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 171. SAMEA 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Application (2021-2026) & (K Dose) Table 172. SAMEA 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Application (2027-2032) & (K Dose) Table 173. SAMEA 23-Valent Pneumococcal Polysaccharide Vaccine Sales Price by Application (2021-2026) & (US$/Dose) Table 174. SAMEA 23-Valent Pneumococcal Polysaccharide Vaccine Sales Price by Application (2027-2032) & (US$/Dose) Table 175. SAMEA 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 176. SAMEA 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 177. SAMEA 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 178. SAMEA 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2021 VS 2025 VS 2032) & (K Dose) Table 179. SAMEA 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2021-2026) & (K Dose) Table 180. SAMEA 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2027-2032) & (K Dose) Table 181. SAMEA 23-Valent Pneumococcal Polysaccharide Vaccine Sales Price by Country (2021-2026) & (US$/Dose) Table 182. SAMEA 23-Valent Pneumococcal Polysaccharide Vaccine Sales Price by Country (2027-2032) & (US$/Dose) Table 183. Brazil 23-Valent Pneumococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 184. Argentina 23-Valent Pneumococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 185. Chile 23-Valent Pneumococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 186. Colombia 23-Valent Pneumococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 187. Peru 23-Valent Pneumococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 188. Saudi Arabia 23-Valent Pneumococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 189. Israel 23-Valent Pneumococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 190. UAE 23-Valent Pneumococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 191. Turkey 23-Valent Pneumococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 192. Iran 23-Valent Pneumococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 193. Egypt 23-Valent Pneumococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Table 194. Key Raw Materials Table 195. Raw Materials Key Suppliers Table 196. 23-Valent Pneumococcal Polysaccharide Vaccine Distributors List Table 197. 23-Valent Pneumococcal Polysaccharide Vaccine Customers List Table 198. Research Programs/Design for This Report Table 199. Authors List of This Report Table 200. Secondary Sources Table 201. Primary Sources List of Figures Figure 1. 23-Valent Pneumococcal Polysaccharide Vaccine Image Figure 2. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size Share 2021 VS 2025 VS 2032 Figure 4. Single Dose Vial Image Figure 5. Pre-filled Syringe Image Figure 6. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size Share 2021 VS 2025 VS 2032 Figure 8. For Children (2-10) Image Figure 9. For Person (10-64) Image Figure 10. For The Old (Above or equal to 65) Image Figure 11. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Figure 13. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 14. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Region: 2025 Versus 2032 Figure 15. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Region (2021-2032) Figure 16. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales (2021-2032) & (K Dose) Figure 17. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Dose) Figure 18. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Region (2021-2032) Figure 19. US & Canada & Mexico 23-Valent Pneumococcal Polysaccharide Vaccine Sales YoY (2021-2032) & (K Dose) Figure 20. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Sales YoY (2021-2032) & (K Dose) Figure 21. China 23-Valent Pneumococcal Polysaccharide Vaccine Sales YoY (2021-2032) & (K Dose) Figure 22. Asia (Excluding China) 23-Valent Pneumococcal Polysaccharide Vaccine Sales YoY (2021-2032) & (K Dose) Figure 23. South America, Middle East and Africa 23-Valent Pneumococcal Polysaccharide Vaccine Sales YoY (2021-2032) & (K Dose) Figure 24. Global 23-Valent Pneumococcal Polysaccharide Vaccine Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 25. Global 23-Valent Pneumococcal Polysaccharide Vaccine Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 26. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 29. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Type (2021-2032) Figure 30. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Type (2021 VS 2025 VS 2032) & (K Dose) Figure 31. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Type (2021-2032) Figure 33. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 34. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 35. Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Application (2021-2032) Figure 36. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Application (2021 VS 2025 VS 2032) & (K Dose) Figure 37. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Application (2021-2032) Figure 39. North America 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Share by Type (2021-2032) Figure 40. North America 23-Valent Pneumococcal Polysaccharide Vaccine Sales Share by Type (2021-2032) Figure 41. North America 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Share by Application (2021-2032) Figure 42. North America 23-Valent Pneumococcal Polysaccharide Vaccine Sales Share by Application (2021-2032) Figure 43. North America 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Share by Country (2021-2032) Figure 44. North America 23-Valent Pneumococcal Polysaccharide Vaccine Sales Share by Country (2021-2032) Figure 45. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Share by Type (2021-2032) Figure 46. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Sales Share by Type (2021-2032) Figure 47. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Share by Application (2021-2032) Figure 48. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Sales Share by Application (2021-2032) Figure 49. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Share by Country (2021-2032) Figure 50. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Sales Share by Country (2021-2032) Figure 51. China 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Share by Type (2021-2032) Figure 52. China 23-Valent Pneumococcal Polysaccharide Vaccine Sales Share by Type (2021-2032) Figure 53. China 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Share by Application (2021-2032) Figure 54. China 23-Valent Pneumococcal Polysaccharide Vaccine Sales Share by Application (2021-2032) Figure 55. Asia 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Share by Type (2021-2032) Figure 56. Asia 23-Valent Pneumococcal Polysaccharide Vaccine Sales Share by Type (2021-2032) Figure 57. Asia 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Share by Application (2021-2032) Figure 58. Asia 23-Valent Pneumococcal Polysaccharide Vaccine Sales Share by Application (2021-2032) Figure 59. Asia 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Share by Country (2021-2032) Figure 60. Asia 23-Valent Pneumococcal Polysaccharide Vaccine Sales Share by Country (2021-2032) Figure 61. SAMEA 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Share by Type (2021-2032) Figure 62. SAMEA 23-Valent Pneumococcal Polysaccharide Vaccine Sales Share by Type (2021-2032) Figure 63. SAMEA 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Share by Application (2021-2032) Figure 64. SAMEA 23-Valent Pneumococcal Polysaccharide Vaccine Sales Share by Application (2021-2032) Figure 65. SAMEA 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Share by Country (2021-2032) Figure 66. SAMEA 23-Valent Pneumococcal Polysaccharide Vaccine Sales Share by Country (2021-2032) Figure 67. 23-Valent Pneumococcal Polysaccharide Vaccine Value Chain Figure 68. Manufacturing Cost Structure Figure 69. 23-Valent Pneumococcal Polysaccharide Vaccine Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Single Dose Vial
  • Pre-filled Syringe
Applications
  • For Children (2-10)
  • For Person (10-64)
  • For The Old (Above or equal to 65)
Companies covered
  • MSD
  • Sanofipasteur
  • CDIBP

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 23-Valent Pneumococcal Polysaccharide Vaccine Market by Type
  3. 1.2.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Single Dose Vial
  5. 1.2.3 Pre-filled Syringe
  6. 1.3 23-Valent Pneumococcal Polysaccharide Vaccine Market by Application
  7. 1.3.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 For Children (2-10)
  9. 1.3.3 For Person (10-64)
  10. 1.3.4 For The Old (Above or equal to 65)
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 23-Valent Pneumococcal Polysaccharide Vaccine Market Dynamics
  1. 2.1 23-Valent Pneumococcal Polysaccharide Vaccine Industry Trends
  2. 2.2 23-Valent Pneumococcal Polysaccharide Vaccine Industry Drivers
  3. 2.3 23-Valent Pneumococcal Polysaccharide Vaccine Industry Opportunities and Challenges
  4. 2.4 23-Valent Pneumococcal Polysaccharide Vaccine Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Region
  3. 3.2.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Region (2021-2026)
  5. 3.2.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Region (2027-2032)
  6. 3.2.4 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Region (2021-2032)
  7. 3.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Region
  9. 3.4.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Region (2021-2026)
  11. 3.4.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Region (2027-2032)
  12. 3.4.4 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Manufacturers
  2. 4.1.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Manufacturers
  6. 4.2.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global 23-Valent Pneumococcal Polysaccharide Vaccine Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global 23-Valent Pneumococcal Polysaccharide Vaccine Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global 23-Valent Pneumococcal Polysaccharide Vaccine Manufacturers, Product Type & Application
  13. 4.7 Global 23-Valent Pneumococcal Polysaccharide Vaccine Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Market CR5 and HHI
  16. 4.8.2 2025 23-Valent Pneumococcal Polysaccharide Vaccine Tier 1, Tier 2, and Tier 3
5 23-Valent Pneumococcal Polysaccharide Vaccine Market by Type
  1. 5.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Type
  2. 5.1.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Type (2021-2032)
  5. 5.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Type
  6. 5.2.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Type (2021-2032) & (K Dose)
  8. 5.2.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Type (2021-2032)
  9. 5.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Price by Type
6 23-Valent Pneumococcal Polysaccharide Vaccine Market by Application
  1. 6.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Application
  2. 6.1.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Application (2021-2032)
  5. 6.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Application
  6. 6.2.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Application (2021-2032) & (K Dose)
  8. 6.2.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Application (2021-2032)
  9. 6.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Price by Application
7 Company Profiles
  1. 7.1 MSD
  2. 7.1.1 MSD Company Information
  3. 7.1.2 MSD Business Overview
  4. 7.1.3 MSD 23-Valent Pneumococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 MSD 23-Valent Pneumococcal Polysaccharide Vaccine Product Portfolio
  6. 7.1.5 MSD Recent Developments
  7. 7.2 Sanofipasteur
  8. 7.2.1 Sanofipasteur Company Information
  9. 7.2.2 Sanofipasteur Business Overview
  10. 7.2.3 Sanofipasteur 23-Valent Pneumococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Sanofipasteur 23-Valent Pneumococcal Polysaccharide Vaccine Product Portfolio
  12. 7.2.5 Sanofipasteur Recent Developments
  13. 7.3 CDIBP
  14. 7.3.1 CDIBP Company Information
  15. 7.3.2 CDIBP Business Overview
  16. 7.3.3 CDIBP 23-Valent Pneumococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 CDIBP 23-Valent Pneumococcal Polysaccharide Vaccine Product Portfolio
  18. 7.3.5 CDIBP Recent Developments
8 North America
  1. 8.1 North America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Type
  2. 8.1.1 North America 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Type (2021-2032)
  3. 8.1.2 North America 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Type (2021-2032)
  4. 8.1.3 North America 23-Valent Pneumococcal Polysaccharide Vaccine Price by Type (2021-2032)
  5. 8.2 North America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Application
  6. 8.2.1 North America 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Application (2021-2032)
  7. 8.2.2 North America 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Application (2021-2032)
  8. 8.2.3 North America 23-Valent Pneumococcal Polysaccharide Vaccine Price by Application (2021-2032)
  9. 8.3 North America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Country
  10. 8.3.1 North America 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America 23-Valent Pneumococcal Polysaccharide Vaccine Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Type
  2. 9.1.1 Europe 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Type (2021-2032)
  3. 9.1.2 Europe 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Type (2021-2032)
  4. 9.1.3 Europe 23-Valent Pneumococcal Polysaccharide Vaccine Price by Type (2021-2032)
  5. 9.2 Europe 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Application
  6. 9.2.1 Europe 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Application (2021-2032)
  7. 9.2.2 Europe 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Application (2021-2032)
  8. 9.2.3 Europe 23-Valent Pneumococcal Polysaccharide Vaccine Price by Application (2021-2032)
  9. 9.3 Europe 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Country
  10. 9.3.1 Europe 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe 23-Valent Pneumococcal Polysaccharide Vaccine Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Type
  2. 10.1.1 China 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Type (2021-2032)
  3. 10.1.2 China 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Type (2021-2032)
  4. 10.1.3 China 23-Valent Pneumococcal Polysaccharide Vaccine Price by Type (2021-2032)
  5. 10.2 China 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Application
  6. 10.2.1 China 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Application (2021-2032)
  7. 10.2.2 China 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Application (2021-2032)
  8. 10.2.3 China 23-Valent Pneumococcal Polysaccharide Vaccine Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Type
  2. 11.1.1 Asia 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Type (2021-2032)
  3. 11.1.2 Asia 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Type (2021-2032)
  4. 11.1.3 Asia 23-Valent Pneumococcal Polysaccharide Vaccine Price by Type (2021-2032)
  5. 11.2 Asia 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Application
  6. 11.2.1 Asia 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Application (2021-2032)
  7. 11.2.2 Asia 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Application (2021-2032)
  8. 11.2.3 Asia 23-Valent Pneumococcal Polysaccharide Vaccine Price by Application (2021-2032)
  9. 11.3 Asia 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Country
  10. 11.3.1 Asia 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia 23-Valent Pneumococcal Polysaccharide Vaccine Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Type
  2. 12.1.1 SAMEA 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Type (2021-2032)
  4. 12.1.3 SAMEA 23-Valent Pneumococcal Polysaccharide Vaccine Price by Type (2021-2032)
  5. 12.2 SAMEA 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Application
  6. 12.2.1 SAMEA 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Application (2021-2032)
  8. 12.2.3 SAMEA 23-Valent Pneumococcal Polysaccharide Vaccine Price by Application (2021-2032)
  9. 12.3 SAMEA 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Country
  10. 12.3.1 SAMEA 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA 23-Valent Pneumococcal Polysaccharide Vaccine Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 23-Valent Pneumococcal Polysaccharide Vaccine Value Chain Analysis
  2. 13.1.1 23-Valent Pneumococcal Polysaccharide Vaccine Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 23-Valent Pneumococcal Polysaccharide Vaccine Production Mode & Process
  6. 13.2 23-Valent Pneumococcal Polysaccharide Vaccine Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 23-Valent Pneumococcal Polysaccharide Vaccine Distributors
  9. 13.2.3 23-Valent Pneumococcal Polysaccharide Vaccine Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst